首页 > 市场调查报告书 > 製药

生物製剂

人类微生物组市场规模、份额和成长分析（按产品、疾病、类型、最终用户和地区划分）—2026-2033年产业预测

市场调查报告书

商品编码

1901915

人类微生物组市场规模、份额和成长分析（按产品、疾病、类型、最终用户和地区划分）—2026-2033年产业预测

Human Microbiome Market Size, Share, and Growth Analysis, By Product (Drugs, Probiotics), By Disease (Infectious Dieases, Gastrointestinal Diseases), By Type, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 201 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，人类微生物组市场规模将达到 13.3 亿美元，到 2025 年将达到 17.5 亿美元，到 2033 年将达到 159.8 亿美元，在预测期（2026-2033 年）内复合年增长率为 31.8%。

由于人类微生物组与呼吸系统和免疫系统健康密切相关，该市场正经历显着成长。肠道微生物组尤其因其在增强免疫功能方面的作用而备受认可。某些微生物群落的紊乱被认为与呼吸系统疾病有关，这推动了基于微生物组的治疗方法的发展，旨在改善包括病毒感染在内的呼吸系统疾病相关健康状况。文明病的日益增加和人口老化进一步推动了市场的扩张。次世代定序和先进的微生物表征技术等进步也在改变该领域的模式。总而言之，不断增加的研究投入以及人们对微生物组及其对健康影响的认识不断提高，是塑造这个蓬勃发展市场未来的关键因素。

人类微生物组市场驱动因素

慢性疾病（例如胃肠道疾病、肥胖症和糖尿病）发病率的不断上升是推动人类微生物组市场发展的主要因素。越来越多的研究表明肠道菌群与这些健康状况密切相关，从而推动了以微生物组为中心的治疗方案和相关研究的需求。医疗保健提供者和患者对微生物组相关问题的认识和兴趣日益增强，促使对微生物组相关产品的研究、创新和商业化投入显着增加。这一趋势凸显了理解微生物组在健康中的作用的重要性，有助于推动治疗方案的进步并改善市场模式。

人类微生物组市场限制因素

人类微生物组领域的一大障碍是研发相关的巨额资金负担。研究微生物并将其转化为有效治疗方法的复杂性需要大量投资。此外，进行临床试验和获得监管核准批准的成本可能非常高昂，阻碍产品创新步伐，并限制整体市场成长。这种资金负担给那些致力于推进产品开发并利用微生物组潜力的公司带来了挑战，最终影响了它们及时向消费者提供新解决方案的能力。

人类微生物组市场趋势

人类微生物组市场正经历着向个人化医疗的显着转变，这反映出人们越来越重视根据每位患者独特的微生物谱量身订做治疗性介入。基因测序和数据分析技术的进步推动了这一转变，使研究人员和製药公司能够开发标靶治疗和诊断方法。因此，医疗服务提供者能够为微生物组相关疾病提供更有效的解决方案，从而改善患者的治疗效果和满意度。这种个人化方法不仅促进了创新治疗方法的开发，也为更深入地了解微生物组在整体健康中的作用铺平了道路，从而激发了人们对这一新兴领域的进一步投资和关注。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Seres Therapeutics, Inc.（US）
Ferring Pharmaceuticals（Switzerland）
Biomebank（Australia）
Nestle SA（Switzerland）
Sanofi（France）
Seed Health, Inc.（US）
Enterome（France）
Pendulum（US）
Quantbiome, Inc.（Dba Ombre）（US）
Vedanta Biosciences, Inc.（US）
Maat Pharma SA（France）
International Flavors & Fragrances, Inc.（US）
Optibiotx Health Plc（UK）
Synlogic, Inc.（US）
Guangzhou Zhiyi Biotechnology Co., Ltd.（China）
Aobiome（US）
Siolta Therapeutics（US）
Alveolus Bio, Inc.（US）
MRM Health NV（Belgium）
Biome Inc（US）
Sanzyme Biologics（India）
Biomx（Israel）
Nubiyota（US）
Quorum Innovations（US）

简介目录

Product Code: SQMIG35H2299

Human Microbiome Market size was valued at USD 1.33 Billion in 2024 and is poised to grow from USD 1.75 Billion in 2025 to USD 15.98 Billion by 2033, growing at a CAGR of 31.8% during the forecast period (2026-2033).

The human microbiome market is witnessing significant growth driven by its crucial connections to respiratory and immune health. The gut microbiome, in particular, is recognized for its role in enhancing immune function. Disruptions in specific microbial populations have been implicated in respiratory issues, prompting the development of microbiome-based therapies aimed at improving health outcomes related to respiratory conditions, including viruses. The rising prevalence of lifestyle-related diseases, alongside an aging population, further propels market expansion. Advances in technology, such as next-generation sequencing and enhanced microbial characterization techniques, are also transforming the landscape. Overall, increased research efforts and heightened awareness of the microbiome's impact on health are key factors shaping the future of this thriving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Human Microbiome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Human Microbiome Market Segments Analysis

Global Human Microbiome Market is segmented by Product, Disease, Type, End User, and region. Based on Product, the market is segmented into Drugs, Probiotics, Prebiotics, and Synbiotics. Based on Disease, the market is segmented into Infectious Dieases, Gastrointestinal Diseases, Endocrine and Metabolic Disorders, and Other Diseases. Based on Type, the market is segmented into Bacterial Consortia Transplantation (BCT)/ Fecal Microbiotia Transplantation (FMT), Live Biotherapeutic Product, and Others. Based on End User, the market is segmented into Hospitals and Clinics, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Human Microbiome Market

The rising incidence of chronic diseases, including gastrointestinal issues, obesity, and diabetes, significantly fuels the human microbiome market. Research increasingly illustrates the connection between gut microbiota and these health conditions, leading to heightened demand for treatment options and investigative studies centered on the microbiome. As awareness and interest grow among both healthcare providers and patients, there is a notable surge in investment toward research, innovation, and the commercialization of microbiome-related products. This trend emphasizes the importance of understanding the microbiome's role in health, driving advances in therapeutic solutions and enhancing the overall market landscape.

Restraints in the Human Microbiome Market

A significant obstacle in the human microbiome sector is the substantial financial burden associated with research and development efforts. The complexities involved in studying microbes and transforming these insights into effective treatments necessitate considerable investment. Additionally, the expenses associated with conducting clinical trials and navigating regulatory approvals can escalate, hindering the pace of product innovation and limiting overall market growth. This financial strain poses a challenge for companies striving to advance their offerings and capitalize on the potential of the microbiome, ultimately impacting their ability to bring new solutions to consumers in a timely manner.

Market Trends of the Human Microbiome Market

The human microbiome market is witnessing a notable trend towards personalized medicine, reflecting a growing emphasis on tailoring therapeutic interventions to individual patients based on their unique microbial profiles. This shift is propelled by advancements in genomic sequencing and data analytics, enabling researchers and pharmaceutical companies to develop targeted treatments and diagnostics. As a result, healthcare providers can offer more effective solutions for microbiota-related diseases, enhancing patient outcomes and satisfaction. This personalized approach not only fosters the development of innovative therapies but also paves the way for a deeper understanding of the microbiome's role in overall health, driving further investment and interest in this evolving field.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Technology Analysis
Patent Analysis
Regulatory Landscape

Human Microbiome Market by Product

Market Overview
Drugs
Probiotics
Prebiotics
Synbiotics

Human Microbiome Market by Disease

Market Overview
Infectious Diseases
Gastrointestinal Diseases
Endocrine & Metabolic Disorders
Other Diseases

Human Microbiome Market by Type

Market Overview
Bacterial Consortia Transplantation (BCT)/ Fecal Microbiotia Transplantation (FMT)
Live Biotherapeutic Product
Others

Human Microbiome Market by End User

Market Overview
Hospitals and Clinics
Long-Term Care Facilities
Other End Users

Human Microbiome Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Seres Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomebank (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nestle S.A. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seed Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Enterome (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pendulum (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quantbiome, Inc. (Dba Ombre) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vedanta Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Maat Pharma SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
International Flavors & Fragrances, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Optibiotx Health Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Synlogic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guangzhou Zhiyi Biotechnology Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aobiome (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siolta Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alveolus Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MRM Health NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biome Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanzyme Biologics (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomx (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nubiyota (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quorum Innovations (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments